<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599053</url>
  </required_header>
  <id_info>
    <org_study_id>F061228003</org_study_id>
    <nct_id>NCT00599053</nct_id>
  </id_info>
  <brief_title>Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates</brief_title>
  <official_title>Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that treatment of known Ureaplasma spp. infection of the airways in very
      low birth weight (VLBW) infants with azithromycin will eradicate the organisms and lessen the
      proinflammatory state caused by infection that puts them at risk for Bronchopulmonary
      Dysplasia (BPD). We propose to conduct a randomized trial of early (less than 3 days of age)
      treatment with intravenous azithromycin versus expectant management for VLBW infants with
      Ureaplasma spp. respiratory tract infection with the following specific aims: (1) Determine
      microbiological efficacy, pharmacokinetics, and safety of azithromycin treatment for
      eradication of Ureaplasma spp. in preterm infants, (2) Determine the respiratory outcomes of
      infants in the two treatment groups and those without respiratory tract Ureaplasma spp.
      infection
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment was terminated early due to a change in practice on the obstetrical side that
    included administering azithromycin to women with preterm labor.
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiological Efficacy of Azithromycin Treatment for Eradication of Ureaplasma Spp. in Preterm Infants</measure>
    <time_frame>100 days or discharge from hospital</time_frame>
    <description>Number of subjects without ureaplasma spp at 100 days after study entry or at hospital discharge in subjects receiving therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of Azithromycin Treatment for Eradication of Ureaplasma Spp. in Preterm Infants</measure>
    <time_frame>100 days or discharge from hospital</time_frame>
    <description>Pharmacokinetic measures (AUC12) of subjects receiving azithromycin who had eradication of ureaplasma spp.at either day 100 or discharge day which ever comes first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Azithromycin Treatment for Eradication of Ureaplasma Spp. in Preterm Infants</measure>
    <time_frame>from day 1 of study drug through 100 days or discharge from hospital, which ever comes first</time_frame>
    <description>Number of serious of adverse event experienced by subjects treated with azithromycin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory Outcomes as Determined by Subjects Without Respiratory Tract Ureaplasma Spp Infection in Subjects in the Two Treatment Groups</measure>
    <time_frame>from baseline to 100 days or discharge from Hospital, which ever comes first</time_frame>
    <description>Absence of Ureaplasma spp infection is determined by the total number of days with positive pressure ventilation, (conventional ventilation or nasal continuous positive pressure) and oxygen therapy. The mean number of days was used to compare the two treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Bacteria Infection</condition>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early treatment with azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Expectant (usual) management</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>10 mg/kg IV per dose given for 10 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants weighing &lt;1250 grams at birth with respiratory distress syndrome who have
             respiratory infection with Ureaplasma sp organisms.

        Exclusion Criteria:

          -  Severe respiratory distress syndrome with survival unlikely &gt;7 days, Congenital
             malformations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L Schelonka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birminham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2008</study_first_posted>
  <results_first_submitted>May 30, 2012</results_first_submitted>
  <results_first_submitted_qc>November 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2012</results_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Robert Schelonka</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ureaplasma</keyword>
  <keyword>Bronchopulmonary dysplasia</keyword>
  <keyword>very low birthweight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Ureaplasma Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Early Treatment With Azithromycin</title>
          <description>Azithromycin (10mg/kg/day) start &lt; 72 hours of age for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Expectant (Usual) Management</title>
          <description>Intervention at the discretion of the attending physician</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early Treatment With Azithromycin</title>
          <description>Azithromycin (10mg/kg/day) start &lt; 72 hours of age for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Expectant (Usual) Management</title>
          <description>Intervention at the discretion of the attending physician</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Microbiological Efficacy of Azithromycin Treatment for Eradication of Ureaplasma Spp. in Preterm Infants</title>
        <description>Number of subjects without ureaplasma spp at 100 days after study entry or at hospital discharge in subjects receiving therapy</description>
        <time_frame>100 days or discharge from hospital</time_frame>
        <population>Unable to determine efficacy due to low enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Early Treatment With Azithromycin</title>
            <description>Azithromycin (10mg/kg/day) start &lt; 72 hours of age for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Expectant (Usual) Management</title>
            <description>Intervention at the discretion of the attending physician</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Efficacy of Azithromycin Treatment for Eradication of Ureaplasma Spp. in Preterm Infants</title>
          <description>Number of subjects without ureaplasma spp at 100 days after study entry or at hospital discharge in subjects receiving therapy</description>
          <population>Unable to determine efficacy due to low enrollment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Outcomes as Determined by Subjects Without Respiratory Tract Ureaplasma Spp Infection in Subjects in the Two Treatment Groups</title>
        <description>Absence of Ureaplasma spp infection is determined by the total number of days with positive pressure ventilation, (conventional ventilation or nasal continuous positive pressure) and oxygen therapy. The mean number of days was used to compare the two treatment groups.</description>
        <time_frame>from baseline to 100 days or discharge from Hospital, which ever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Treatment With Azithromycin</title>
            <description>Azithromycin (10mg/kg/day) start &lt; 72 hours of age for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Expectant (Usual) Management</title>
            <description>Intervention at the discretion of the attending physician</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Outcomes as Determined by Subjects Without Respiratory Tract Ureaplasma Spp Infection in Subjects in the Two Treatment Groups</title>
          <description>Absence of Ureaplasma spp infection is determined by the total number of days with positive pressure ventilation, (conventional ventilation or nasal continuous positive pressure) and oxygen therapy. The mean number of days was used to compare the two treatment groups.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="09.4" lower_limit="0" upper_limit="23"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK) of Azithromycin Treatment for Eradication of Ureaplasma Spp. in Preterm Infants</title>
        <description>Pharmacokinetic measures (AUC12) of subjects receiving azithromycin who had eradication of ureaplasma spp.at either day 100 or discharge day which ever comes first.</description>
        <time_frame>100 days or discharge from hospital</time_frame>
        <population>Unable to determine Pharmacokinetics (PK) data due to low enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Early Treatment With Azithromycin</title>
            <description>Azithromycin (10mg/kg/day) start &lt; 72 hours of age for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Expectant (Usual) Management</title>
            <description>Intervention at the discretion of the attending physician</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) of Azithromycin Treatment for Eradication of Ureaplasma Spp. in Preterm Infants</title>
          <description>Pharmacokinetic measures (AUC12) of subjects receiving azithromycin who had eradication of ureaplasma spp.at either day 100 or discharge day which ever comes first.</description>
          <population>Unable to determine Pharmacokinetics (PK) data due to low enrollment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety of Azithromycin Treatment for Eradication of Ureaplasma Spp. in Preterm Infants</title>
        <description>Number of serious of adverse event experienced by subjects treated with azithromycin</description>
        <time_frame>from day 1 of study drug through 100 days or discharge from hospital, which ever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Treatment With Azithromycin</title>
            <description>Azithromycin (10mg/kg/day) start &lt; 72 hours of age for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Expectant (Usual) Management</title>
            <description>Intervention at the discretion of the attending physician</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Azithromycin Treatment for Eradication of Ureaplasma Spp. in Preterm Infants</title>
          <description>Number of serious of adverse event experienced by subjects treated with azithromycin</description>
          <units>number of events</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>enrollment through 100 days or discharge which ever is first</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Early Treatment With Azithromycin</title>
          <description>Azithromycin (10mg/kg/day) start &lt; 72 hours of age for 10 days</description>
        </group>
        <group group_id="E2">
          <title>Expectant (Usual) Management</title>
          <description>Intervention at the discretion of the attending physician</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to small number enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. David Randolph</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-4680</phone>
      <email>drandolph@peds.uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

